The Ministry of Health, Labor and Welfare reported the death of a man after receiving the Novavax COVID shot, which is the first fatality associated with the Novavax vaccine in Japan.
Uncertainty surrounds the cause of a 29-year-old man’s death in Japan one day after receiving the COVID-19 vaccine shot from American pharmaceutical company Novavax Inc.
On September 2, the man’s death was reported by the Ministry of Health, Labor and Welfare during a meeting of an expert panel to assess the safety of vaccines. Despite a report from the medical facility to the ministry stating that “It was a sudden death, and a link with vaccination such as the possibility of heart muscle inflammation cannot be denied,” a causal relation reportedly could not be proven due to a lack of objective facts. This was the first fatality associated with the Novavax vaccine to be reported in Japan.
The man was given a second vaccination, per the health ministry, on August 17. The following morning, he started feeling feverish, and he was recovering at home. The man was taken to the hospital after experiencing cardiopulmonary arrest in the evening, but he was later declared dead.
The fourth COVID-19 vaccine to receive the Japanese government’s approval is Novavax’s serum, which is produced domestically by Takeda Pharmaceutical Co., which was given the technology needed. Recombinant protein vaccines have been utilised for both first and second doses as well as booster shots.
Subscribe to GreatGameIndia